Cardiovascular manifestations in rheumatoid arthritis;Kardiovaskuläre manifestationen bei rheumatoider arthritis

Zeitschrift fur Rheumatologie

Volumn 64, Issue 4, 2005, Pages 222-228

  Moritz, F ^a,b   Wagner, U ^c   Distler, O ^a,b   Seidel, W ^c   Gay, S ^a,b   Hantzschel H ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Universität Leipzig ^*  (Switzerland)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cardiovascular risk; Endothelial dysfunction; Rheumatoid arthritis; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; HUMAN; IMMUNOPATHOLOGY; JOINT DESTRUCTION; MORTALITY; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COMORBIDITY; HUMANS; INTERNATIONALITY; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 21244479418     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-005-0732-6     Document Type: Review

References (70)

1. Goodson N (2002) Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 14(2):115-120
2. Turesson C, Jarenros A, Jacobsson L (2004) Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63(8):952-955
3. Maradit-Kremers H et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52(2):402-411
4. del Rincon ID et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44(12):2737-2745
5. Gabriel SE et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48(1)54-58
6. Turesson C et al (2002) Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29(1):62-67
7. Vita JA, Keaney JF Jr (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106(6):640-642
8. Iversen PO et al (1999) Human cytokines modulate arterial vascular tone via endothelial receptors. Pflugers Arch 439(1-2)93-100
9. True AL, Rahman A, Malik AB (2000) Activation of NF-kappaB induced by H(2)O(2) and TNF-alpha and its effects on ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol 279(2)L302-L311
10. Tellides G et al (2000) Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 403 (6766):207-211
11. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789):373-376
12. Quyyumi AA et al (1995) Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 95(4):1747-1755
13. Hida A et al (2004) Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis. J Lab Clin Med 144(3):148-155
14. Qian H et al (1999) Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 99(23):2979-2982
15. De Caterina R et al (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96(1):60-68
16. Tomita H et al (1998) Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 18(9):1456-1464
17. Loscalzo J (2001) Inducible NO synthesis in the vasculature: molecular context defines physiological response. Arterioscler Thromb Vasc Biol 21(8):1259-1260
18. Bouchie JL, Hansen H, Feener EP (1998) Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 18(11):1771-1779
19. Yoshizumi M et al (1993) Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 73(1):205-209
20. Anderson HD, Rahmutula D, Gardner DG (2004) Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 279(2):963-969
21. Ito A et al (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99(24):3092-3095
22. Madge LA, Pober JS (2001) TNF signaling in vascular endothelial cells. Exp Mol Pathol 70(3):317-325
23. Hurlimann D et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106(17):2184-2187
24. Fichtlscherer S et al (2001) Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104(25):3023-3025
25. Haverkate F et al (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349(9050):462-466
26. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340(2):115-126
27. Escribano-Burgos M et al (2005) Effect of C-reactive protein on Fcgamma receptor II in cultured bovine endothelial cells. Clin Sci (Lond) 108(1):85-91
28. Verma S et al (2002) A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106(8): 913-919
29. Verma S et al (2003) C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 126(6):1886-1891
30. Wang CH et al (2003) C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107(13):1783-1790
31. Blaschke F et al (2004) C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 110(5):579-587
32. Fu T, Borensztajn J (2002) Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J 366(Pt 1):195-201
33. Li L et al (2004) C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95(9):877-883
34. Verma S et al (2004) C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109(17):2058-2067
35. Grisar J et al (2005) Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis, in Circulation, pp 204-211
36. Kuwana M et al (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364(9434):603-610
37. Zwaal RP, Schroit AJ (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89(4):1121-1132
38. Berckmans RJ et al (2002) Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 46(11):2857-2866
39. Distler JH et al (2005) The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA
40. Brogan PA et al (2004) Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 50(3):927-936
41. Nieuwland R et al (2000) Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 95(3):930-935
42. Joop K et al (2001) Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 85(5):810-820
43. Huber J et al (2002) Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 22(1): 101-107
44. Brodsky SV et al (2004) Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 286(5):H1910-H1915
45. Mack M et al (2000) Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 6(7):769-775
46. Mesri M, Altieri DC (1999) Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 274(33):23111-23118
47. Martin S et al (2004) Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 109(13):1653-1659
48. Paolisso G et al (1991) Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 40(9):902-907
49. Kiortsis DN et al (2004) Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis
50. Hallgren R, Berne C (1983) Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 213(5):351-355
51. Khovidhunkit W et al (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45(7):1169-1196
52. Lee YH et al (2000) Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 19(4):324-325
53. Chae CU et al (2001) Blood pressure and inflammation in apparently healthy men. Hypertension 38(3): 399-403
54. Schmidt D et al (1996) The repertoire of CD4+ CD28-T cells in rheumatoid arthritis. Mol Med 2(5):608-618
55. Liuzzo G et al (2000) Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101(25):2883-2888
56. Weyand CM, Fulbright JW, Goronzy JJ (2003) Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 38(8):833-841
57. Wagner UG et al (1998) Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 95(24):14447-14452
58. Martens PB et al (1997) Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 40(6):1106-1114
59. Pawlik A et al (2003) The expansion of CD4+CD28-T cells in patients with rheumatoid arthritis. Arthritis Res Ther 5(4):R210-R213
60. Namekawa T et al (1998) Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 41(12): 2108-2116
61. Gerli R et al (2004) CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109(22): 2744-2748
62. Monaco C et al (2002) T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. J Leukoc Biol 71(4):659-668
63. Pawlik A et al (2004) Therapy with infliximab decreases the CD4+CD28-T cell compartment in peripheral blood in patients with rheumatoid arthritis. Rheumatol Int 24(6):351-354
64. Wagner U et al (2003) Prospective analysis of the impact of HLA-DR and - DQ on joint destruction in recent-onset rheumatoid arthritis. Rheumatology (Oxford) 42(4):553-562
65. Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30(11):1205-1213
66. Gonzalez-Juanatey C et al (2003) HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114(8):647-652
67. Gorman JD et al (2004) Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 50(11):3476-3484
68. Wolfe F et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37(4):481-494
69. Goodson NJ et al (2002) Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46(8):2010-2019
70. Heliovaara M et al (1995) Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis 54(10):811-814